Skip to content
2000
image of Prevention of Chemotherapy-related Oral Mucositis by Topical Timolol: A Prospective Randomized, Double-blind, Placebo-controlled Clinical Trial in Cancer Patients

Abstract

Background

Timolol is a beta-adrenergic blocker that has been shown to be effective in the healing of wounds. Oral mucositis (OM), an acute inflammation of the oral mucosa, is a bothersome side effect of some regimens of chemotherapy in which the oral mucosa becomes ulcerated. The current study aimed to evaluate the prophylactic effects of timolol mouthwash in preventing OM in adult patients receiving chemotherapy compared to the placebo.

Methods

This randomized, double-blind trial was conducted on 30 adult patients receiving chemotherapy regimen, including doxorubicin or 5-fluorouracil (5-FU). The patients were randomized in a 1:1 ratio to receive either timolol 0.5% (w/v) (n = 15) or placebo (n = 15) mouthwash 5 ml three times per day. The outcomes of the study were the intensity of OM evaluated by the World Health Organization (WHO) mucositis scale and OM-related pain based on the Visual Analog Scale (VAS) weekly during the seven weeks of the study period.

Results

The results of the study showed that the scores of WHO mucositis scale significantly decreased in the timolol group compared to the control group during the study [week 1: mean (SD), 0.02 (0.41) in the timolol group, and 0.67 (0.48) in the control group; week 7: mean (SD), 0.33 (0.61) in the timolol group, and 0.87 (0.74) in the control group; = 0.049]. Moreover, the mean pain scores significantly decreased in the first, second, and third weeks in the timolol group compared to the control group (P-value < 0.05).

Conclusion

The results of this preliminary clinical trial demonstrated that among the patients receiving doxorubicin or 5-FU chemotherapy regimens, the preventive use of timolol mouthwash significantly diminished the severity of OM compared to the control group during the seven weeks of follow-up. The severity of pain was also significantly lower during the first three weeks of the study; however, the effect size was less than the minimal clinically important difference. Further studies are required to assess both the long-term efficacy and safety of timolol mouthwash in preventing OM.

Clinical Trial Registration Number

IRCT20190810044500N9.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/raiad/10.2174/0127722708312485250115052258
2025-01-24
2025-09-01

  • From This Site

    /content/journals/raiad/10.2174/0127722708312485250115052258
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Sung H. Ferlay J. Siegel R.L. Laversanne M. Soerjomataram I. Jemal A. Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2021 71 3 209 249 10.3322/caac.21660 33538338
    [Google Scholar]
  2. Dewhirst M.W. Secomb T.W. Transport of drugs from blood vessels to tumour tissue. Nat. Rev. Cancer 2017 17 12 738 750 10.1038/nrc.2017.93 29123246
    [Google Scholar]
  3. Sahebnasagh A Ghasemi A Akbari J Alipour A Lashkardoost H Ala S Prevention of acute radiation-induced Proctitis by Aloe vera: A prospective randomized, double-blind, placebo controlled clinical trial in Pelvic Cancer patients. BMC Complement Med Ther 2020 20 1 146 10.1186/s12906‑020‑02935‑2
    [Google Scholar]
  4. Scardina G.A. Pisano T. Messina P. Oral mucositis. Review of literature. N. Y. State Dent. J. 2010 76 1 34 38 20359063
    [Google Scholar]
  5. Redman M.G. Harris K. Phillips B.S. Low-level laser therapy for oral mucositis in children with cancer. Arch. Dis. Child. 2021 34230010
    [Google Scholar]
  6. Shetty S.S. Maruthi M. Dhara V. de Arruda J.A.A. Abreu L.G. Mesquita R.A. Teixeira A.L. Silva T.A. Merchant Y. Oral mucositis: Current knowledge and future directions. Dis. Mon. 2022 68 5 101300 10.1016/j.disamonth.2021.101300 34758917
    [Google Scholar]
  7. Biswal B.M. Current trends in the management of oral mucositis related to cancer treatment. Malays. J. Med. Sci. 2008 15 3 4 13 22570584
    [Google Scholar]
  8. Rodrigues-Oliveira L. Kowalski L.P. Santos M. Marta G.N. Bensadoun R.J. Martins M.D. Lopes M.A. Castro G. Jr William W.N. Jr Chaves A.L.F. Migliorati C.A. Salloum R.G. Rodrigues-Fernandes C.I. Kauark-Fontes E. Brandão T.B. Santos-Silva A.R. Prado-Ribeiro A.C. Direct costs associated with the management of mucositis: A systematic review. Oral Oncol. 2021 118 105296 10.1016/j.oraloncology.2021.105296 33933777
    [Google Scholar]
  9. Jayakeerthana S. Awareness of night brushing among local population. Int. J. Sci. Dev. Res. 2021 6 3
    [Google Scholar]
  10. Nguyen H. Sangha S. Pan M. Shin D.H. Park H. Mohammed A.I. Cirillo N. Oxidative stress and chemoradiation-induced oral mucositis: A scoping review of in vitro and in vivo and clinical studies. Int. J. Mol. Sci. 2022 23 9 4863 10.3390/ijms23094863 35563254
    [Google Scholar]
  11. Singh V. Singh A. Oral mucositis. Natl. J. Maxillofac. Surg. 2020 11 2 159 168 10.4103/njms.NJMS_10_20 33897175
    [Google Scholar]
  12. Lalla R.V. Sonis S.T. Peterson D.E. Management of oral mucositis in patients who have cancer. Dent. Clin. North Am. 2008 52 1 61 77, viii 10.1016/j.cden.2007.10.002 18154865
    [Google Scholar]
  13. Supportive P. Board P.C.E. Oral complications of chemotherapy and head/neck radiation (PDQ®). PDQ Cancer Information Summaries. US National Cancer Institute 2016
    [Google Scholar]
  14. Yang H. Steenhuis P. Glucksman A.M. Gurenko Z. La T.D. Isseroff R.R. Alpha and beta adrenergic receptors modulate keratinocyte migration. PLoS One 2021 16 7 e0253139 10.1371/journal.pone.0253139 34214097
    [Google Scholar]
  15. Thomas B. Kurien J.S. Jose T. Ulahannan S.E. Varghese S.A. Topical timolol promotes healing of chronic leg ulcer. J. Vasc. Surg. Venous Lymphat. Disord. 2017 5 6 844 850 10.1016/j.jvsv.2017.04.019 29037357
    [Google Scholar]
  16. Pullar C. Manabathidalgo C. Bolaji R. Isseroff R. β-Adrenergic receptor modulation of wound repair. Pharmacol. Res. 2008 58 2 158 164 10.1016/j.phrs.2008.07.012 18790719
    [Google Scholar]
  17. Goodarzi A. Mozafarpoor S. Dodangeh M. Seirafianpour F. Shahverdi M.H. The role of topical timolol in wound healing and the treatment of vascular lesions: A narrative review. Dermatol. Ther. 2021 34 2 e14847 10.1111/dth.14847 33538017
    [Google Scholar]
  18. Pullar C.E. Le Provost G.S. O’Leary A.P. Evans S.E. Baier B.S. Rivkah Isseroff R. β2AR antagonists and β2AR gene deletion both promote skin wound repair processes. J. Invest. Dermatol. 2012 132 8 2076 2084 10.1038/jid.2012.108 22495178
    [Google Scholar]
  19. Migliazzo C.V. Hagan J.C. III Beta blocker eye drops for treatment of acute migraine. Mo. Med. 2014 111 4 283 288 25211851
    [Google Scholar]
  20. Pullar C.E. Rizzo A. Isseroff R.R. β-Adrenergic receptor antagonists accelerate skin wound healing: Evidence for a catecholamine synthesis network in the epidermis. J. Biol. Chem. 2006 281 30 21225 21235 10.1074/jbc.M601007200 16714291
    [Google Scholar]
  21. Gomes A. Costa D. Lima J.L.F.C. Fernandes E. Antioxidant activity of β-blockers: An effect mediated by scavenging reactive oxygen and nitrogen species? Bioorg. Med. Chem. 2006 14 13 4568 4577 10.1016/j.bmc.2006.02.023 16510286
    [Google Scholar]
  22. Turan B. A comparative summary on antioxidant-like actions of timolol with other antioxidants in diabetic cardiomyopathy. Curr. Drug Deliv. 2016 13 3 418 423 10.2174/1567201813666151123103354 26593438
    [Google Scholar]
  23. Kwon Y. Mechanism-based management for mucositis: Option for treating side effects without compromising the efficacy of cancer therapy. OncoTargets Ther. 2016 9 2007 2016 10.2147/OTT.S96899 27103826
    [Google Scholar]
  24. Izzotti A. Saccà S.C. Di Marco B. Penco S. Bassi A.M. Antioxidant activity of timolol on endothelial cells and its relevance for glaucoma course. Eye (Lond.) 2008 22 3 445 453 10.1038/sj.eye.6702737 17293786
    [Google Scholar]
  25. Wu H.W. Wang X. Zhang L. Zheng J.W. Liu C. Wang Y.A. Topical timolol vs. oral propranolol for the treatment of superficial infantile hemangiomas. Front. Oncol. 2018 8 605 10.3389/fonc.2018.00605 30619747
    [Google Scholar]
  26. Tong S. Xu D.P. Liu Z.M. Du Y. Wang X.K. Evaluation of the efficacy and safety of topical timolol maleate combined with oral propranolol treatment for parotid mixed infantile hemangiomas. Oncol. Lett. 2016 12 3 1806 1810 10.3892/ol.2016.4818 27588127
    [Google Scholar]
  27. Bahramsoltani R. Medicinal plants for chemoradiotherapy-induced oral mucositis: A review of clinical studies. J Trad Integrative Med. 2017 196 207
    [Google Scholar]
  28. Owusu-Boadi E Akuoko Essuman M Mensah G Ayamba Ayimbissa E Boye A. Antimicrobial activity against oral pathogens confirms the use of musa paradisiaca fruit stalk in ethnodentistry. Evid Based. Complement. Alternat. Med 2021 8663210 2021 10.1155/2021/8663210
    [Google Scholar]
  29. Seyed Hashemi M. Hashempur M.H. Lotfi M.H. Hemat H. Mousavi Z. Emtiazy M. Vaziri F. The efficacy of asafoetida (Ferula assa-foetida oleo-gum resin) versus chlorhexidine gluconate mouthwash on dental plaque and gingivitis: A randomized double-blind controlled trial. Eur. J. Integr. Med. 2019 29 100929 10.1016/j.eujim.2019.100929
    [Google Scholar]
  30. Mousavi SM Hashemi SA Behbudi G Mazraedoost S Omidifar N Gholami A A Review on health benefits of Malva sylvestris L. nutritional compounds for metabolites, antioxidants, and anti-inflammatory, anticancer, and antimicrobial applications. Evid Based Complement Alternat Med 2021 2021 5548404
    [Google Scholar]
  31. Agha-Hosseini F. Pourpasha M. Amanlou M. Moosavi M.S. Mouthwash containing vitamin E, Triamcinolon, and Hyaluronic Acid compared to triamcinolone mouthwash alone in patients with radiotherapy-induced oral mucositis: Randomized clinical trial. Front. Oncol. 2021 11 614877 10.3389/fonc.2021.614877 33777752
    [Google Scholar]
  32. Gilani SA Gilani NA Feroz F Faizan M Murtaza G Combination of Chlorhexidine with magic mouth wash for the prophylaxes of chemotherapy induced mucositis. Global Sci. J. 2021 9 5
    [Google Scholar]
  33. Lin Z. Chen J. Han S. The efficacy of heat-clearing (Qingre) and Detoxifying (Jiedu) traditional chinese medicine gargle for chemotherapy-induced oral mucositis: A systematic review and meta-analysis. Front. Pharmacol. 2021 12 627628 10.3389/fphar.2021.627628 33854434
    [Google Scholar]
  34. Meyer-Hamme G Beckmann K Radtke J Efferth T Greten HJ Rostock M A survey of chinese medicinal herbal treatment for chemotherapy-induced oral mucositis. Evid Based Complement Alternat Med. 2013 2013 284959 10.1155/2013/284959
    [Google Scholar]
  35. Aulton ME Taylor K Aulton's pharmaceutics: The design and manufacture of medicines. Elsevier 6th ed 2013
    [Google Scholar]
  36. Metwaly HAM Ebrahem MA-M Hussein FF Evaluation of the efficacy of topical timolol therapy on oral lichen planus: Clinical and immunohistochemical study. J. adv. med. 2017 24 8 1 13 10.9734/JAMMR/2017/37603
    [Google Scholar]
  37. Nyström B. Kjøniksen A.L. Beheshti N. Maleki A. Zhu K. Knudsen K.D. Pamies R. Hernández Cifre J.G. García de la Torre J. Characterization of polyelectrolyte features in polysaccharide systems and mucin. Adv. Colloid Interface Sci. 2010 158 1-2 108 118 10.1016/j.cis.2009.05.003 19482258
    [Google Scholar]
  38. Julious S.A. Sample size of 12 per group rule of thumb for a pilot study. Pharmaceutical Statistics. J. Appl. Stat. 2005 4 4 287 291
    [Google Scholar]
  39. Saghaei M. Random allocation software for parallel group randomized trials. BMC Med. Res. Methodol. 2004 4 1 26 10.1186/1471‑2288‑4‑26 15535880
    [Google Scholar]
  40. Scully C. Sonis S. Diz P.D. Oral mucositis. Oral Dis. 2006 12 3 229 241 10.1111/j.1601‑0825.2006.01258.x 16700732
    [Google Scholar]
  41. Maria O.M. Eliopoulos N. Muanza T. Radiation-induced oral mucositis. Front. Oncol. 2017 7 89 10.3389/fonc.2017.00089 28589080
    [Google Scholar]
  42. Lalla R.V. Bowen J. Barasch A. Elting L. Epstein J. Keefe D.M. McGuire D.B. Migliorati C. Nicolatou-Galitis O. Peterson D.E. Raber-Durlacher J.E. Sonis S.T. Elad S. Mucositis Guidelines Leadership Group of the Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASCC/ISOO) MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer 2014 120 10 1453 1461 10.1002/cncr.28592 24615748
    [Google Scholar]
  43. Peterson D.E. Bensadoun R.J. Roila F. ESMO Guidelines Working Group Management of oral and gastrointestinal mucositis: ESMO clinical practice guidelines. Ann. Oncol. 2011 22 Suppl 6 Suppl. 6 vi78 vi84 10.1093/annonc/mdr391 21908510
    [Google Scholar]
  44. Eubank P.L.C. Abreu L.G. Violante I.P. Volpato L.E.R. Medicinal plants used for the treatment of mucositis induced by oncotherapy: A systematic review. Support. Care Cancer 2021 29 11 6981 6993 10.1007/s00520‑021‑06247‑0 33988743
    [Google Scholar]
  45. Steinmann D. Babadağ Savaş B. Felber S. Joy S. Mertens I. Cramer H. Paul A. Layer M. Klafke N. Stolz R. Heyder U. Neuberger P. Winkler M. Idler C. Heine R. Kaschdailewitsch E. John H. Schmeling B. Zielke T. Horneber M. Witt C.M. Voiss P. Nursing procedures for the prevention and treatment of mucositis induced by cancer therapies: Clinical practice guideline based on an interdisciplinary consensus process and a systematic literature search. Integr. Cancer Ther. 2021 20 1534735420940412 10.1177/1534735420940412 33467951
    [Google Scholar]
  46. Scully C. Epstein J. Sonis S. Oral mucositis: A challenging complication of radiotherapy, chemotherapy, and radiochemotherapy: Part 1, pathogenesis and prophylaxis of mucositis. Head Neck 2003 25 12 1057 1070 10.1002/hed.10318 14648865
    [Google Scholar]
  47. Lyle R.E. Budhiraja A. Mehta A. Dahle S.E. Isseroff R.R. The use of timolol for wound healing—A review. Curr. Dermatol. Rep. 2024 13 1 8 27 10.1007/s13671‑024‑00421‑3
    [Google Scholar]
  48. Jia S. Wang X. Wang G. Wang X. Mechanism and application of β‐adrenoceptor blockers in soft tissue wound healing. Med. Res. Rev. 2024 44 1 422 452 10.1002/med.21984 37470332
    [Google Scholar]
  49. Tang J.C. Dosal J. Kirsner R.S. Topical timolol for a refractory wound. Dermatol. Surg. 2012 38 1 135 138 10.1111/j.1524‑4725.2011.02200.x 22093053
    [Google Scholar]
  50. Dabiri G. Tiger J. Goreshi R. Fischer A. Iwamoto S. Topical timolol may improve overall scar cosmesis in acute surgical wounds. Cutis 2017 100 1 E27 E28 28873118
    [Google Scholar]
  51. Sung L. Tomlinson G.A. Greenberg M.L. Koren G. Judd P. Ota S. Feldman B.M. Validation of the oral mucositis assessment scale in pediatric cancer. Pediatr. Blood Cancer 2007 49 2 149 153 10.1002/pbc.20863 16628556
    [Google Scholar]
/content/journals/raiad/10.2174/0127722708312485250115052258
Loading
Prevention of Chemotherapy-related Oral Mucositis by Topical Timolol: A Prospective Randomized, Double-blind, Placebo-controlled Clinical Trial in Cancer Patients
Bentham Science Publishers ; https://doi.org/10.2174/0127722708312485250115052258
/content/journals/raiad/10.2174/0127722708312485250115052258
/content/journals/raiad/10.2174/0127722708312485250115052258
Loading

Data & Media loading...

Supplements

Supplementary material is available on the publisher's website along with the published article.

file format download Download

  • Article Type:     Research Article
Keywords: Chemotherapy-induced mucositis ; mouthwash ; timolol ; neoplasms

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test